"uuid:ID","name","label","description","id","instanceType","rationale"
"ec8c0c70-bae8-4bf0-ac92-13bfffafe8c4","Study Design 1","","The main design for the study","StudyDesign_1","StudyDesign","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated."
